Our analysis associated low expression of MAP3K6 with better progression-free survival thus suggesting other than the tumor suppressor role for MAP3K6 in PCa and that MAP3K6 inhibition could suppress tumor growth also in prostate cancer. Here, MAP3K6 is linked to posterior cortical atrophy.